2021 FDA Endocrinology Approvals: Novel Small Molecules Deep Dive
In 2021, the FDA approved two new drugs for endocrinology-related indications, including severe hypoglycemia in diabetes, and chronic kidney disease (CKD) associated with type 2 diabetes. This article and slide deck explores each in more detail, including but not limited to their: target rationale discovery disease context original patents key clinical data pharmacokinetics industry history
Molecules of the Month – April 2022
Drug Hunter’s April 2022 edition of Molecules of the Month features some emerging small molecule clinical candidates as well as several interesting molecules in preclinical stages for a broad range of indications. Among these are two KRASG12C inhibitors, JDQ443 from Novartis and AZD4625 from AstraZeneca, each with unique chemical structure and binding modes, which set them…
Drug Hunter
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.